mdCurrent Conference Report: 72nd annual scientific sessions of the American Diabetes Association Intensive therapy initiated in newly diagnosed patients with type 2 diabetes preserved beta-cell function over the course of a 3.5-year study. The study’s lead investigator, Ildiko Lingvay, MD, recommended that “we try to achieve glycemic normalization as quickly…
Read more »
mdCurrent Conference Report: 72nd Annual Scientific Sessions of the American Diabetes Association Basal insulin in patients with prediabetes or newly diagnosed type 2 diabetes has no effect on cardiovascular disease events over a median follow-up of 6.2 years, according to a recent study. An estimated 62 million people nationwide are…
Read more »
Postmenopausal women with type 2 diabetes that requires treatment with insulin demonstrated an increased risk for developing lung cancer, according to an analysis of the Women’s Health Initiative (WHI) study. “Physicians in India should screen diabetes patients, especially women, for lung cancer, particularly those on insulin therapy.” -Vijay Viswanathan, MD,…
Read more »
The addition of metformin to insulin therapy in patients with type 2 diabetes does not significantly impact all-cause or cardiovascular mortality, although the combination reduced hemoglobin A1C values, weight gain, and insulin doses, a recent study found. Combining metformin to insulin also may increase the risk of hypoglycemia. According to…
Read more »
indicates a Peer-Reviewed Article
Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes
Type 2 diabetes mellitus (T2DM) is characterized by increasing insulin resistance and an inexorable decline in β-cell function, with patients with T2DM usually requiring treatment intensification to achieve and maintain…
Read more »